This study seeks to determine whether patients who have received a device called an implantable cardioverter-defibrillator (ICD), and who are considered to be at a high risk for certain dangerous heart rhythm disorders, will have fewer of these negative outcomes if they are treated with a drug called Ranolazine. Positive results would add a valuable treatment option for many patients.

This study is being conducted at approximately 70 centers across the United States, and is funded by National Institutes of Health grant U01 HL096607. The principal investigator at Weill Cornell Cardiology is Dr. George Thomas. The study is currently open to enrollment: see studies open to enrollment.

Research Category: